摘要
We previously reported that an interferon (IFN)-inducible protein, BST2, was regulated by the JAK-STAT pathway activated by CD40, and subsequently suppressing hepatitis B virus (HBV) repliaction and transcription. The current research attempted to assess the impact of BST2 on the IFN-treated anti-HBV effect, and explore BST2 variants for predicting pegylated IFN alpha (PegIFN alpha) therapy response of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). Using an HBV-transfected cell model, the function of BST2 on HBV DNA replication and transcription driven by IFN was studied. The potentially functional BST2 variants were selected through a strategy of gene-wide screening. The associations of BST2 variants and polygenic score (PGS) model, which was used to quantify the combined influence of several genetic variants, with treatment response were examined in 2 separate PegIFN alpha-treated cohorts of 238 and 707 patients with CHB, respectively. We found that overexpression of BST2 improved the anti-HBV activity triggered by IFN-alpha. Among PegIFN alpha-treated patients with CHB, BST2_rs9576 was screened out to be significantly correlated with combined response (CR; i.e., HBeAg seroconversion along with HBV DNA level <3.3log(10)IU/mL, P = 7.12 x 10(-5)). Additionally, there was a strong correlation between the PGS incorporating BST2_rs9576 and other 5 genetic variations (previously described predictors of therapy response to PegIFN alpha) and CR (P = 1.81 x 10(-13)), hepatitis B surface antigen (HBsAg) level (P = 0.004), as well as HBsAg decline (P = 0.017). In conclusion, higher BST2 expression responded better to IFN-alpha treatment. BST2_rs9576 is an effective indicator to forecast therapy response of PegIFN alpha-treated patients with CHB. The PGS possesses the potential to boost the ability of PegIFN alpha therapy response.
学科与关键词
- An intronic genetic variant of ZHX2 predicts response to pegylated interferon α therapy in HBeAg-positive chronic hepatitis B patientsHou, Jia; Dong, Chao; Chen, Jiaxuan; Chen, Haitao; Na, Rong; Zhou, Bin; Hou, Jinlin*; Jiang, De-Ke*Antiviral Research, 2023, 220: 105741.
- CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B PatientsChen, Jiaxuan; Lou, Shuang; Chen, Haitao; Zhou, Bin; Sun, Jian; Hou, Jinlin; Jiang, De-Ke*Journal of Clinical and Translational Hepatology, 2022, 11(2): 295-303.被引 3
- The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon α TherapyLou, Shuang; Wang, Jialin; Chen, Jiaxuan; Xie, Haisheng; Chen, Haitao; Zhou, Bin; Zhang, Bo; Hou, Jinlin; Jiang, De-Ke*JOURNAL OF INFECTIOUS DISEASES, 2023, 228(6): 694-703.
